A Class Action Lawsuit Against Hims & Hers Health, Inc.: Investor Alert

Investor Alert: Class Action Lawsuit Against Hims & Hers Health, Inc.

On October 1, 2026, Pomerantz LLP announced a significant development for investors in Hims & Hers Health, Inc. (NYSE: HIMS). A class action lawsuit has been initiated that could impact many stakeholders connected to the telehealth company. Investors who have experienced losses related to their Hims & Hers investments are being urged to take action and consider joining this legal effort.

Overview of the Class Action Lawsuit

The lawsuit raises serious concerns regarding allegations of securities fraud and other unlawful business practices against Hims & Hers, particularly involving its management team. Investors who acquired Hims & Hers securities during the class period are encouraged to contact Pomerantz LLP to discuss their potential status as class members and the specifics of their claims. The firm is inviting affected investors to reach out to Danielle Peyton via email or phone, providing their details for further action and guidance.

As the legal action unfolds, it is crucial for interested individuals to be aware that the deadline to apply for Lead Plaintiff status is November 2, 2026. This status allows investors to step forward as representatives in this crucial case, which could lead to significant recoveries for victims of the alleged misconduct.

Allegations by the Federal Trade Commission

In the wake of the class action announcement, news emerged from the Federal Trade Commission (FTC) regarding separate allegations against Hims & Hers. On July 29, 2026, it was reported that the FTC had filed a lawsuit alleging that the company mishandled sensitive health information of its consumers. Specifically, the FTC claimed that Hims & Hers shared personal data with third-party advertising platforms, contradicting its promises of privacy.

Additionally, the FTC raised issues about Hims & Hers' billing practices, stating that consumers were charged for prescriptions shortly after submitting health information without proper disclosure. The allegations also indicated that the company misrepresented how thoroughly users would consult with a medical provider, thus misleading customers about the purchasing process.

The fallout from these FTC announcements was immediate and severe; Hims & Hers’ stock price plummeted by $4.32 per share, a staggering drop of 14.73%, closing at $25.00 per share following the news.

The Role of Pomerantz LLP

Recognized as one of the leading firms in corporate and securities class litigation, Pomerantz LLP has gained a reputation over its 85 years of operation for representing class members effectively in numerous high-stakes lawsuits. Founded by renowned attorney Abraham L. Pomerantz, the firm continues to uphold his legacy by working diligently to protect investor rights and pursue remedies for breaches of fiduciary duty and corporate misconduct.

Pomerantz LLP has successfully recovered significant damages for many clients in past securities fraud cases. Investors who feel aggrieved by their experience with Hims & Hers are now presented with a formidable opportunity to join the class action and be part of the collective effort to hold the company accountable.

Next Steps for Investors

For those affected by their association with Hims & Hers Health, Inc., it is crucial to assess your rights as investors keenly. Contacting Pomerantz LLP is an essential first step to understanding the implications of the class action and determining your potential involvement. Be proactive and consider the possibilities for compensation should the court find in favor of the class members.

For further details on joining this class action lawsuit, interested parties can visit Pomerantz LLP's official website. As this legal battle develops, all eyes will be on Hims & Hers to see how it navigates the numerous allegations currently against it and what the implications will be for both the company and its investors going forward.